Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer

PurposeAs treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with a prognostic and predictive role could guide treatment. We tested the hypothesis that circulating tumor cells (CTCs) could predict clinical outcome in patients with mCRC.Patients and MethodsIn a prospective multicenter study, CTCs were enumerated in the peripheral blood of 430 patients with mCRC at baseline and after starting first-, second-, or third-line therapy. CTCs were measured using an immunomagnetic separation technique.ResultsPatients were stratified into unfavorable and favorable prognostic groups based on CTC levels of three or more or less than three CTCs/7.5 mL, respectively. Patients with unfavorable compared with favorable baseline CTCs had shorter median progression-free survival (PFS; 4.5 v 7.9 months; P = .0002) and overall survival (OS; 9.4 v 18.5 months; P < .0001). Differences persisted at 1 to 2, 3 to 5, 6 to 12, and 13 to 20 weeks after therapy. Conversion of baseline unfavorable CTCs to favorable at 3 to 5 weeks was associated with significantly longer PFS and OS compared with patients with unfavorable CTCs at both time points (PFS, 6.2 v 1.6 months; P = .02; OS, 11.0 v 3.7 months; P = .0002). Among nonprogressing patients, favorable compared with unfavorable CTCs within 1 month of imaging was associated with longer survival (18.8 v 7.1 months; P < .0001). Baseline and follow-up CTC levels remained strong predictors of PFS and OS after adjustment for clinically significant factors.ConclusionThe number of CTCs before and during treatment is an independent predictor of PFS and OS in patients with metastatic colorectal cancer. CTCs provide prognostic information in addition to that of imaging studies.

Download Full-text

The Detection of Stem-Like Circulating Tumor Cells Could Increase the Clinical Applicability of Liquid Biopsy in Ovarian Cancer

Life ◽

10.3390/life11080815 ◽

2021 ◽

Vol 11 (8) ◽

pp. 815

Author(s):

Snezhanna O. Gening ◽

Tatyana V. Abakumova ◽

Dina U. Gafurbaeva ◽

Albert A. Rizvanov ◽

Inna I. Antoneeva ◽

...

Keyword(s):

Ovarian Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Cancer Progression ◽

Cox Regression ◽

Progression Free Survival ◽

First Line ◽

Free Survival ◽

Cox Regression Analysis ◽

Paired Samples

Stem properties allow circulating tumor cells (CTCs) to survive in the bloodstream and initiate cancer progression. We aimed to assess the numbers of stem-like CTCs in patients with ovarian cancer (OC) before treatment and during first-line chemotherapy (CT). Flow cytometry was performed (Cytoflex S (Beckman Coulter, CA, USA)) using antibodies against CD45; epithelial markers EpCAM and cytokeratin (CK) 8,18; mesenchymal vimentin (vim); and stem-like CD44, CD133 and ALDH. This study included 38 stage I–IV OC patients (median age 66 (Q1–Q3 53–70)). The CK+vim- counts were higher (p = 0.012) and the CD133+ALDHhigh counts were lower (p = 0.010) before treatment in the neoadjuvant CT group than in the adjuvant group. The patients with ascites had more CK+vim- cells before treatment (p = 0.009) and less EpCAM-vim+ cells during treatment (p = 0.018) than the patients without ascites. All the CTC counts did not differ significantly in paired samples. Correlations were found between the CK-vim+ and CD133+ALDHhigh (r = 0.505, p = 0.027) and EpCAM-vim+ and ALDHhigh (r = 0.597, p = 0.004) cells before but not during treatment. Multivariate Cox regression analysis showed that progression-free survival was longer with the presence of surgical treatment (HR 0.06 95% CI 0.01–0.48, p = 0.009) and fewer CD133+ALDHveryhigh cells (HR 1.06 95% CI 1.02–1.12, p = 0.010). Thus, CD133+ALDH+ CTCs have the greatest prognostic potential in OC among the phenotypes studied.

Download Full-text

The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2007.08.088 ◽

2008 ◽

Vol 108 (1) ◽

pp. 100-105 ◽

Cited By ~ 54

Author(s):

M.S. Carey ◽

M. Bacon ◽

D. Tu ◽

L. Butler ◽

A. Bezjak ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Overall Survival ◽

Performance Status ◽

Advanced Ovarian Cancer ◽

Progression Free Survival ◽

Free Survival

Download Full-text

The Relationship Between Retroperitoneal Lymphadenectomy and Survival in Advanced Ovarian Cancer Patients

10.21203/rs.2.14760/v1 ◽

2019 ◽

Author(s):

Ping Zhang ◽

Chenyan Fang ◽

Yingli Zhang ◽

Lingqin Zhao ◽

Xi Chen ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Postoperative Complications ◽

Lymph Nodes ◽

Cancer Patients ◽

Advanced Ovarian Cancer ◽

Progression Free Survival ◽

Residual Tumor ◽

Retroperitoneal Lymphadenectomy ◽

Free Survival

Abstract Background Systematic retroperitoneal lymphadenectomy has been widely used in the surgical treatment of advanced ovarian cancer patients; nevertheless, the effect remains controversial. Thus, the current study was carried out aiming to evaluate the benefit of systematic retroperitoneal lymphadenectomy in such patients with optimal cytoreduction. Methods Patients with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III-IV) admitted and treated in Zhejiang Cancer Hospital from January 2004 to December 2013 were enrolled and reviewed retrospectively. All patients were optimally debulked (residual tumor <1 cm or absent) and divided into two groups. Group A (n =170) (no-lymphadenectomy group): patients did not undergo lymph node resection; lymph nodes resection or biopsy were selective. Group B (n=240): patients underwent systematic retroperitoneal lymphadenectomy. Results A total of 410 eligible patients were enrolled in the analysis. The median age was 51 years (range: 28–72). The 5-year overall survival (OS) and 2-year progression-free survival (PFS) rates were 78% and 24% in the no-lymphadenectomy group and 76% and 26% in the lymphadenectomy group (P=0.385 and P=0.214, respectively). Subsequently, there was no significant difference in 5-year overall survival and 2-year progression-free survival between the two groups stratified to histological type (serous or non-serous type), the clinical evaluation for lymph nodes (negative) or with macroscopic peritoneal metastasis beyond pelvic (IIIB-IV). Multivariate Cox regression analysis indicated that systematic retroperitoneal lymphadenectomy was not a significant factor affecting survival of patients. Patients in the lymphadenectomy group had a higher incidence of postoperative complications (incidence of infection treated with antibiotics was 21.7% vs. 12.9% [P=0.027]; incidence of lymph cysts was 20.8% vs. 2.4% [P < 0.001]). Conclusions Our study showed that systematic retroperitoneal lymphadenectomy did not significantly improve survival in advanced ovarian cancer patients with residual tumor <1 cm or absent after cytoreductive surgery, and were associated with a higher incidence of postoperative complications.

Download Full-text

Isolation of Circulating Tumor Cells of Ovarian Cancer by Transferrin Immunolipid Magnetic Spheres and Its Preliminary Clinical Application

Nano LIFE ◽

10.1142/s1793984419400014 ◽

2019 ◽

Vol 09 (01n02) ◽

pp. 1940001 ◽

Cited By ~ 2

Author(s):

Li Zuo ◽

Wei Niu ◽

Anqi Li

Keyword(s):

Ovarian Cancer ◽

Survival Rate ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Peripheral Blood ◽

Progression Free Survival ◽

Cancer Prognosis ◽

Free Survival ◽

Magnetic Spheres ◽

Positive Rate

Circulating tumor cells (CTCs) play an important role in cancer prognosis, treatment monitoring and metastasis diagnosis. However, due to the extremely low concentration of CTC in the peripheral blood, its isolation and enrichment are critical steps for early diagnosis. Herein, we used the transferrin modified lipid magnetic spheres for the isolation of ovarian cancer CTCs, and studied the relationship between the CTCs count and the clinical case parameters, prognosis of ovarian cancer. The result showed that no CTC was found in the peripheral blood of 30 patients with benign cysts, and 34 out of 46 patients with ovarian cancer were positive for CTC, with a positive rate of 73.9%. Analysis of the parameters of the clinical cases showed that the positive rate of CTC was related to the clinical stages, and that it was not significantly related to the age, histopathological types and pathological grades of patients. Of the 34 CTC-positive patients, 18 had progression-free survival, with a survival rate of 52.9%, and of the 11 CTC-negative patients, 9 had progression-free survival, with a survival rate of 81.8%. The results showed that the transferrin lipid magnetic spheres prepared in this study, could effectively isolate the CTCs in the peripheral blood of patients with ovarian cancer, that the level of CTC in ovarian cancer patients was related to its clinical stage, and that the progression-free survival of the patients with a high level of CTCs was relatively short. Therefore, this study shows that the transferrin lipid magnetic sphere can achieve effective isolation of ovarian cancer CTC, which can be used as an auxiliary diagnostic method in comprehensive diagnosis of ovarian cancer.

Download Full-text